Cautious Optimism for Nautilus Biotechnology Amid Promising Developments and Delayed Commercial Launch

Yuko Oku, an analyst from Morgan Stanley, maintained the Hold rating on Nautilus Biotechnolgy (NAUT – Research Report). The associated price target remains the same with $3.00.

Yuko Oku has given his Hold rating due to a combination of factors related to Nautilus Biotechnology’s current position and future prospects. The company is making notable progress in developing its proteomics platform, which is a positive sign. However, the anticipated commercial launch is not expected until late 2026, which suggests that significant stock appreciation might be limited in the near term.
Additionally, Nautilus is actively working towards establishing partnerships, particularly in the area of Tau-related proteoform studies, with expectations to secure an initial partnership by the first half of 2025. While these developments are promising, the current financial outlook and market conditions suggest a cautious approach, justifying the Hold rating until more concrete advancements are realized.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NAUT in relation to earlier this year.